Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EFTR
- Price
- 0.00
- Stock movement up
- +- (%)
- Company name
- Effector Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 941.00
- Ent value
- 10.80M
- Price/Sales
- 0.01
- Price/Book
- 0.00
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -100.00%
- 3 year return
- -98.83%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
EFTR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.01 |
| Price to Book | 0.00 |
| EV to Sales | 66.65 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 4.70M |
| EPS (TTM) | -8.48 |
| FCF per share (TTM) | -7.17 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 162.00K |
| Gross profit (TTM) | 51.00K |
| Operating income (TTM) | -33.15M |
| Net income (TTM) | -34.63M |
| EPS (TTM) | -8.48 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 31.48% |
| Operating margin (TTM) | -20463.58% |
| Profit margin (TTM) | -21376.54% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.51M |
| Net receivables | 17.00K |
| Total current assets | 26.25M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 767.00K |
| Total assets | 27.13M |
| Accounts payable | 1.71M |
| Short/Current long term debt | 20.25M |
| Total current liabilities | 25.57M |
| Total liabilities | 26.30M |
| Shareholder's equity | 827.00K |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -29.19M |
| Capital expenditures (TTM) | 84.00K |
| Free cash flow (TTM) | -29.27M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -4187.42% |
| Return on Assets | -127.64% |
| Return on Invested Capital | -174.93% |
| Cash Return on Invested Capital | -147.88% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.00 |
| Daily high | 0.00 |
| Daily low | 0.00 |
| Daily Volume | 0K |
| All-time high | 679.25 |
| 1y analyst estimate | 10.00 |
| Beta | 0.80 |
| EPS (TTM) | -8.48 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| EFTR | S&P500 | |
| Current price drop from All-time high | -100.00% | -14.41% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -82.49% | -11.07% |
| Avg time to new high | 195 days | 12 days |
| Max time to new high | 864 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
941.00
Marketcap category
Small-cap
Description
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Employees
14
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page